Mostrar registro simples

dc.contributor.authorMoura, Karolinny Borinelli de Aquinopt_BR
dc.contributor.authorBehrens, Paula Marques Pratespt_BR
dc.contributor.authorPirolli, Rafaelapt_BR
dc.contributor.authorSauer, Aimée Bianchessipt_BR
dc.contributor.authorSandoval, Dayana Esther Melamedpt_BR
dc.contributor.authorVeronese, Francisco José Veríssimopt_BR
dc.contributor.authorSilva, André Luis Ferreira dapt_BR
dc.date.accessioned2020-02-01T04:14:49Zpt_BR
dc.date.issued2019pt_BR
dc.identifier.issn2048-8513pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/205317pt_BR
dc.description.abstractBackground. The aim of this study was to report the prevalence and mortality associated with anticoagulant-related nephropathy (ARN) through a systematic review of the literature. Methods. Electronic searches were conducted in the Medline and EMBASE databases, and manual searches were performed in the reference lists of the identified studies. The studies were selected by two independent researchers, first by evaluating the titles and abstracts and then by reading the complete texts of the identified studies. Case series, cross-sectional studies, cohort studies and case–control studies reporting the prevalence and factors associated with ARN were selected. The methodological quality was assessed using the Newcastle–Ottawa scale. Meta-analyses of the prevalence of ARN and 5-year mortality using the random effects model were performed when possible. Heterogeneity was assessed using the I 2 statistic. Results. Five studies were included. Prevalence of ARN ranged from 19% to 63% among the four included cohort studies. Meta-analysis of these resulted in high heterogeneity [I 2 96%, summary effect 31%; 95% confidence interval (CI) 22–42%]. Subgroup meta-analysis yielded an ARN prevalence of 20% among studies that included patients with fewer comorbidities (I 2 12%; 95% CI 19–22%). In a direct comparison, meta-analysis of the 5-year mortality rate between anticoagulated patients who had experienced ARN and anticoagulated patients without ARN, patients with ARN were 91% more likely to die (risk ratio ¼ 1.91; 95% CI 1.22–3; I 2 87%). Risk factors for ARN that were reported in the literature included initial excessive anticoagulation, chronic kidney disease, age, diabetes, hypertension, cardiovascular disease and heart failure. Conclusions. ARN studies are scarce and heterogeneous, and present significant methodological limitations. The high prevalence of ARN reported herein suggests that this entity is underdiagnosed in clinical practice. Mortality in patients with ARN seems to be high compared with patients without this condition in observational studies.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofClinical Kidney Journal. Oxford. Vol. 12, no. 3 (2019), p. 400–407pt_BR
dc.rightsOpen Accessen
dc.subjectAnticoagulant-related nephropathyen
dc.subjectHematúriapt_BR
dc.subjectMeta-analysisen
dc.subjectLesão renal agudapt_BR
dc.subjectInsuficiência renal crônicapt_BR
dc.subjectSystematic reviewen
dc.subjectWarfarinen
dc.subjectMortalidadept_BR
dc.subjectPrevalênciapt_BR
dc.subjectWarfarin-related nephropathyen
dc.subjectAnticoagulantespt_BR
dc.subjectVarfarinapt_BR
dc.subjectRevisão sistemáticapt_BR
dc.subjectMetanálisept_BR
dc.titleAnticoagulant-related nephropathy : systematic review and meta-analysispt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001107648pt_BR
dc.type.originEstrangeiropt_BR


Thumbnail
   

Este item está licenciado na Creative Commons License

Mostrar registro simples